Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Axitinib (Inlyta™)

Last Updated: 03/28/17

Status: Currently a NF2 Clinical Trial


  1. Basic Information
  2. Important Information
  3. NF2 Clinical Trial
  4. Other Known Uses
  5. Side Effects
  6. Recommendation

1. Basic Information

Other Names Axitinib, Inlyta, 319460-85-0, AG-013736, AG 013736; UNII-C9LVQ0YUXG, AG013736, S1005_Selleck, AG-013736, AG-13736
Trade Name Inlyta™
Pharmaceutical Company Pfizer
Treatment By Pill - Oral
Tumor Target Vestibular Schwannoma
NF2 Trials Recruiting Trial: NCT02129647
Inhibitor TKI Small Molecule - Tyrosine Kinase Inhibitor and Vascular Epidermal Growth Factor Receptor
Molecular Formula C22H18N4OS
IUPAC N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
ChemSpider 4953153
PubChem CID 6450551

2. Other Known Uses

  • Breast Cancer
  • Renal Cell Carcinoma (RCC)
  • In Research for: Mesothelioma

3. Side Effects

  • High Blood Pressure / Nosebleeds
  • Diarrhea
  • Fatigue / Tiredness
  • Decrease in Appetite
  • Nausea / Vomiting
  • Hoarseness / Dry Thrroat
  • Skin Conditions - Dry Skin and Blisters
  • Constipation

4. Recommendation

  • Drinking extra water or diluted fluids as well as avoiding fatty, fried, spicy, or highly sweet foods can help with many of the potential side effects.
  • Take Axitinib at night instead of the morning to prevent fatigue.